Allowing the federal government to negotiate drug prices would shift costs to consumers, PCMA says

08/19/2011 | Atlantic Information Services

Options being considered by Congress to reduce Medicare drug spending might instead raise prices for consumers if enacted. In particular, allowing the federal government to negotiate drug pricing directly with manufacturers would shift costs, according to the Pharmaceutical Care Management Association. "Allowing the federal government to 'negotiate' prescription drug prices would result in a significant cost shift to consumers enrolled in existing employer-provided drug coverage," PCMA Assistant Vice President for Strategic Communications Charles Coté said.

View Full Article in:

Atlantic Information Services